Lenti-D gene therapy: Phase II/III started

bluebird began the open-label Phase II/III Starbeam trial to evaluate Lenti-D gene therapy in up to 15 male patients ages <=17 years. The product has Orphan Drug designation in the U.S. and EU to trea...